In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Iron plays a major role in the growth and virulence of ferrophilic organisms like Vibrio vulnificus. People who reside in the coastal areas with raw fish eating habits have a high risk of Vibrio infection and aggressive therapy can only reduce their mortality. We investigated the in vitro efficacy of ciprofloxacin, a bactericidal drug used in V. vulnificus patients, and the orally active iron chelator deferasirox against V. vulnificus infection. We performed in vitro time-kill studies on two ATCC strains and one clinical isolate of V. vulnificus collected from a patient admitted to Chosun University Hospital with either ciprofloxacin or iron chelator deferasirox alone and the two drugs in combination. The combination of an iron chelator plus an antibiotic creates a novel form of synergism at 24 h. The antimicrobial effect of deferasirox may be ascribed to its ability to deplete iron that would otherwise be used for bacterial growth. Combination therapy with ciprofloxacin plus deferasirox has potential clinical application by lowering the iron availability against a ferrophilic organism like V. vulnificus infections.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“how synergistic a combination is does depend on the exact speciation of the liganded iron”
In the citing paper
“the iron chelator deferasirox promoted the antibacterial activity of ciprofloxacin against V. vulnificus (Neupane and Kim 2010), as did deferiprone with various azoles against Aspergillus fumigatus, while deferoxamine was antagonistic to azoles (Zarember et al. 2009)”
Citations
Cites
Klontz, K. C., Lieb, S., Schreiber, M., Janowski, H. T., Baldy, L. M., & Gunn, R. A. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-4-318 · Cited by 403
Bacterial Assimilation of iron
Lankford, C. E., & Byers, B. R. (1973) · CRC Critical Reviews in Microbiology · doi:10.3109/10408417309108388 · Cited by 345
Iron and infection: the heart of the matter
Bullen, J. J., Rogers, H. J., Spalding, P. B., & Ward, C. G. (2005) · FEMS Immunology & Medical Microbiology · doi:10.1016/j.femsim.2004.11.010 · Cited by 273
Vibrio vulnificus infection: diagnosis and treatment.
Bross, M. H., Soch, K., Morales, R. E., & Mitchell, R. B. (2007) · PubMed · Cited by 194
Vibrio vulnificus infection: clinical manifestations, pathogenesis, and antimicrobial therapy.
Chiang, & Chuang, Y.-C. (2003) · PubMed · Cited by 170
Siderophore production by Vibrio vulnificus
Simpson, L. M., & Oliver, J. D. (1983) · Infection and Immunity · doi:10.1128/iai.41.2.644-649.1983 · Cited by 167
Iron: Mammalian defense systems, mechanisms of disease, and chelation therapy approaches
Kontoghiorghes, G. J., & Weinberg, E. D. (1995) · Blood Reviews · doi:10.1016/0268-960x(95)90038-1 · Cited by 134 · cited 1×
“Hence, in some patients treated with iron chelator such as deferoxamine in whom yersiniosis or mucormycosis was promoted, the drug may have enhanced the growth of a microbial or neoplastic cell invader by acting as a siderophore instead of assisting the host [17].”
BackgroundIn Vitro and In Vivo Activities of Newer Fluoroquinolones against Vibrio vulnificus
Tang, H.-J., Chang, M.-C., Ko, W., Huang, K.-Y., Lee, C.-L., & Chuang, Y.-C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3580-3584.2002 · Cited by 107
In vitro synergism between cefotaxime and minocycline against Vibrio vulnificus
Chuang, Y. C., Liu, J. W., Ko, W. C., Lin, K. Y., Wu, J. J., & Huang, K. Y. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2214 · Cited by 67
In Vivo Efficacy of the Combination of Ciprofloxacin and Cefotaxime against Vibrio vulnificus Sepsis
Jang, H., Choi, S., Kim, H. K., Kim, S., Kang, S., Park, K., Ryu, P. Y., Lee, T., Kim, Y. R., Rhee, J. H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101118 · Cited by 52
Cited by
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
“…of the liganded iron; surprisingly, the iron chelator deferasirox promoted the antibacterial activity of ciprofloxacin against V. vulnificus (Neupane and Kim 2010), as did deferiprone with various azoles against Aspergillus fumigatus, while deferoxamine was antagonistic to azoles (Zarember…”
BackgroundHorseman, M. A., & Surani, S. (2011) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2010.11.003 · Cited by 343
Wu, Y., Ran, L., Yang, Y., Gao, X., Peng, M., Liu, S., Sun, L., Wan, J., Wang, Y., Yang, K., et al. (2023) · Life Sciences · doi:10.1016/j.lfs.2022.121312 · Cited by 228
Genetics, epidemiology, and clinical manifestations of multidrug-resistant Acinetobacter baumannii
Nasr, P. (2019) · Journal of Hospital Infection · doi:10.1016/j.jhin.2019.09.021 · Cited by 159
Antibacterial Activities of Iron Chelators against Common Nosocomial Pathogens
Thompson, M. G., Corey, B. W., Si, Y., Craft, D. W., & Zurawski, D. V. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01197-12 · Cited by 135
Metadata
- Authors
- Neupane, G. P., & Kim, D.-M.
- Affiliations
- Chosun University (KR)
- Corresponding author
- Kim, D.-M.
- ORCID
- Kim, D.-M.
- Venue
- European Journal of Clinical Microbiology & Infectious Diseases
- Published
- 2010-02-02
- Volume
- 29
- Issue
- 4
- Pages
- 407-410
- ISSN
- 0934-9723 (ISSN-L)
- 1435-4373
- OpenAlex
- W2031369396
- Cited by
- 29
- References
- 19
- Citations by year
- 2025: 1 · 2024: 1 · 2022: 2 · 2021: 5 · 2020: 2 · 2019: 1 · 2018: 3 · 2016: 1 · 2015: 3 · 2014: 1 · 2013: 2 · 2012: 3
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Clinical Microbiology & Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Vibrio bacteria research studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
- Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
- Keywords
- Vibrio vulnificus, ciprofloxacin, deferasirox, iron chelation, combination therapy, antibiotic synergy, time-kill kinetics, iron availability, Vibrio vulnificus infection, clinical isolates
- MeSH terms
- Deferasirox, Anti-Bacterial Agents, Benzoates, Chelating Agents, Ciprofloxacin, Drug Synergism, Hospitals, Humans, Microbial Sensitivity Tests, Time Factors, Triazoles, Vibrio Infections, Vibrio vulnificus, Microbial Viability, Republic of Korea
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus. https://app.cochat.ai/papers/10.1007/s10096-010-0875-5
- The paper
- Neupane, G. P., & Kim, D.-M. (2010). In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus. European Journal of Clinical Microbiology & Infectious Diseases. https://doi.org/10.1007/s10096-010-0875-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.